Cancer Causes & Control

, Volume 25, Issue 7, pp 915–922 | Cite as

Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program

  • Birgitte Baldur-Felskov
  • Christian Dehlendorff
  • Jette Junge
  • Christian Munk
  • Susanne K. Kjaer
Original paper



Approximately 70 % of cervical cancers and about 50 % of high-grade cervical precursor lesions are caused by human papillomavirus (HPV) types 16 and 18. Denmark introduced the quadrivalent HPV vaccine into the vaccination program for 12-year-old girls in 2009 supplemented by a first catch-up program for 13–15-year-old girls in 2008, and a second program for women up to the age of 27 years in 2012; all with high vaccination coverage. The aim of this study was to evaluate the effectiveness of the vaccine by comparing the incidence trends of cervical lesions before and after its introduction.


Incident cases of cervical lesions were identified from the nationwide Pathology Data Bank. Age-specific incidence rates were estimated for six age groups, and Poisson regression was used to calculate estimated annual percentage change (EAPC).


The incidence of atypia or worse (atypia+) and cervical intraepithelial neoplasia grade 2 or worse (CIN2+) increased in all age groups in 2000–2010. After introduction of the quadrivalent HPV vaccine into the vaccination program, the incidence of atypia+ decreased significantly in women younger than 18 years (EAPC −33.4 %; 95 % CI −49.6; −12.0) and in 18–20-year-old women (EAPC −12.6 %; 95 % CI −19.3; −5.3). The incidence of CIN2+ also decreased significantly in 18–20-year-old women (EAPC −14.8 %; 95 % CI −21.6; −7.5) in 2010–2013, but no significant decrease was seen in older age groups.


The incidence of cervical lesions decreased significantly in age groups with high HPV vaccine coverage, indicating an early effect of HPV vaccination.


HPV Vaccination Incidence Cervical lesions Nationwide Denmark 



The study was supported by the Mermaid project (MERMAID II).

Conflict of interest

Birgitte Baldur-Felskov and Christian Dehlendorff declare no potential conflicts of interest. Jette Junge received advisory board fee from Sanofi Pasteur MSD and consultant fee from Merck. Christian Munk received travel and speaker’s fees from Sanofi Pasteur MSD. Susanne K. Kjaer received advisory board and speaker’s fees and institutional research grants from Sanofi Pasteur MSD and Merck.


  1. 1.
    Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19PubMedCrossRefGoogle Scholar
  2. 2.
    Weaver BA (2006) Epidemiology and natural history of genital human papillomavirus infection. J Am Osteopath Assoc 106:S2–S8PubMedGoogle Scholar
  3. 3.
    Moscicki AB, Schiffman M, Burchell A et al (2012) Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 30(Suppl 5):F24–F33PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    European Medicines Agency (2010) European public assessment report for Gardasil. Accessed Sept 2013
  5. 5.
  6. 6.
    Sander BB, Rebolj M, Valentiner-Branth P, Lynge E (2012) Introduction of human papillomavirus vaccination in Nordic countries. Vaccine 30:1425–1433PubMedCrossRefGoogle Scholar
  7. 7.
    Statens Serum Institut (2013) EPI-NYT: HPV-vaccination - tilslutning 2012. Accessed Sept 2013
  8. 8.
    Garland SM, Smith JS (2010) Human papillomavirus vaccines: current status and future prospects. Drugs 70:1079–1098PubMedCrossRefGoogle Scholar
  9. 9.
    Smith JS, Lindsay L, Hoots B et al (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121:621–632PubMedCrossRefGoogle Scholar
  10. 10.
    Kjaer SK, Munk C, Junge J, Iftner T (2013) Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? Cancer Causes Control. doi: 10.1007/s10552-013-0320-z PubMedCentralGoogle Scholar
  11. 11.
    Stanley M (2010) Pathology and epidemiology of HPV infection in females. Gynecol Oncol 117:S5–S10PubMedCrossRefGoogle Scholar
  12. 12.
    Schiller JT, Castellsague X, Garland SM (2012) A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30(Suppl 5):F123–F138PubMedCrossRefGoogle Scholar
  13. 13.
    Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370:890–907PubMedCrossRefGoogle Scholar
  14. 14.
    Niccolai LM, Julian PJ, Meek JI, McBride V, Hadler JL, Sosa LE (2013) Declining rates of high-grade cervical lesions in young women in Connecticut, 2008–2011. Cancer Epidemiol Biomarkers Prev 22:1446–1450PubMedCrossRefGoogle Scholar
  15. 15.
    Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM (2011) Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 377:2085–2092PubMedCrossRefGoogle Scholar
  16. 16.
    Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM (2013) Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 11:227. doi: 10.1186/1741-7015-11-227 PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    The Danish Pathology Data Bank (2011). Accessed Sept 2013
  18. 18.
    McCullagh P, Nelder JA (1989) Generalized linear models. Chapman and Hall, London ISBN-10: 0412317605CrossRefGoogle Scholar
  19. 19.
    R Development Core Team (2012) R: a language and environment for statistical computing. Auckland: R Foundation for Statistical Computing. Vienna, Austria. ISBN 3-900051-07-0. Accessed Oct 2013
  20. 20.
    Harrell FE Jr (2013) rms: Regression modeling strategies. R package version 3.6-3. Accessed Oct 2013
  21. 21.
    Markowitz LE, Hariri S, Lin C et al (2013) Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 208:385–393PubMedCrossRefGoogle Scholar
  22. 22.
    Cummings T, Zimet GD, Brown D et al (2012) Reduction of HPV infections through vaccination among at-risk urban adolescents. Vaccine 30:5496–5499PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK (2011) The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 87:544–547PubMedCrossRefGoogle Scholar
  24. 24.
    Bauer HM, Wright G, Chow J (2012) Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007–2010. Am J Public Health 102:833–835PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK (2013) Significant decrease in the incidence of genital warts in young danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 40:130–135PubMedGoogle Scholar
  26. 26.
    Leval A, Herweijer E, Arnheim-Dahlstrom L et al (2012) Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 206:860–866PubMedCrossRefGoogle Scholar
  27. 27.
    Ali H, Donovan B, Wand H et al (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 346:f2032PubMedCrossRefGoogle Scholar
  28. 28.
    Blomberg M, Dehlendorff C, Munk C, Kjaer SK (2013) Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 57:929–934PubMedCrossRefGoogle Scholar
  29. 29.
    Leval A, Herweijer E, Ploner A et al (2013) Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst 105:469–474PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Tabrizi SN, Brotherton JM, Kaldor JM et al (2012) Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 206:1645–1651PubMedCrossRefGoogle Scholar
  31. 31.
    Powell SE, Hariri S, Steinau M et al (2012) Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 31:109–113PubMedCrossRefGoogle Scholar
  32. 32.
    Statens Serum Institut (2013) Indberetning og patient registrering: Patologi. Accessed Nov 2013
  33. 33.
    Danske Regioner (2012) Økonomisk vejledning 2008, 2010, 2011 and 2012.økonomi/økonomisk+vejledning/baggrundsmappe2007og2008/regionernes+bidrag+til+patobanken+i+2008. Accessed Nov 2013Google Scholar
  34. 34.
    Dugue PA, Lynge E, Bjerregaard B, Rebolj M (2012) Non-participation in screening: the case of cervical cancer in Denmark. Prev Med 54:266–269PubMedCrossRefGoogle Scholar
  35. 35.
    Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J (2008) Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 111:167–177PubMedCrossRefGoogle Scholar
  36. 36.
    Barken SS, Rebolj M, Lynge E, Junge J, Rygaard C (2013) Outcomes in cervical screening using various cytology technologies: what’s age got to do with it? Eur J Cancer Prev 22:367–373PubMedCrossRefGoogle Scholar
  37. 37.
    Rask J, Lynge E, Franzmann M et al (2013) Impact of technology on cytology outcome in cervical cancer screening of young and older women. Int J Cancer. doi: 10.1002/ijc.28532 PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Birgitte Baldur-Felskov
    • 1
  • Christian Dehlendorff
    • 2
  • Jette Junge
    • 3
  • Christian Munk
    • 1
  • Susanne K. Kjaer
    • 1
    • 4
  1. 1.Virus, Lifestyle and GenesDanish Cancer Society Research CenterCopenhagenDenmark
  2. 2.Statistics, Bioinformatics and RegistryDanish Cancer Society Research CenterCopenhagenDenmark
  3. 3.Department of PathologyHvidovre University HospitalHvidovreDenmark
  4. 4.Gynaecological Clinic, Juliane Marie CentreRigshospitalet, Copenhagen University HospitalCopenhagenDenmark

Personalised recommendations